Growth & profitability
- Revenue has grown 8.4% per year over the past 5 years.
- Operating margin has expanded, at -3.4% in the latest year.
Financial health
- Operating income covered interest expense -1.5× in the latest year.
TBPH Financials Theravance Biopharma, Inc.
14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $107M | $106M | 0.0% | -3.4% | 35.7% | 21.8% | $238M | — | $168M |
| 2024 | $64M | -$56M | 0.0% | -72.9% | -32.1% | -15.9% | -$12M | — | $38M |
| 2023 | $57M | -$55M | 0.0% | -97.6% | -25.9% | -14.4% | -$29M | $0 | $40M |
| 2022 | $51M | $872M | 0.0% | -179.1% | 197.4% | 143.6% | -$188M | — | $298M |
| 2021 | $55M | -$199M | 0.0% | -466.1% | 58.9% | -53.2% | -$211M | $616M | $90M |
| 2020 | $72M | -$278M | 0.0% | -414.2% | 91.5% | -59.3% | -$257M | $619M | $81M |
| 2019 | $73M | -$236M | 0.0% | -343.1% | 105.6% | -57.8% | -$241M | $455M | $58M |
| 2018 | $60M | -$216M | 0.0% | -395.5% | 417.8% | -38.5% | -$120M | $454M | $378M |
| 2017 | $15M | -$285M | 60.8% | -1690.6% | -247.8% | -64.7% | -$203M | $224M | $89M |
| 2016 | $49M | -$191M | 94.1% | -371.0% | -54.4% | -29.8% | -$101M | — | $345M |
| 2015 | — | -$182M | — | — | -75.0% | -60.7% | -$172M | — | $113M |
| 2014 | — | -$237M | — | — | -81.8% | -70.2% | — | — | $89M |
| 2013 | — | -$156M | — | — | 917.4% | -620.7% | — | — | $0 |
| 2012 | — | -$10M | — | — | 137.0% | — | — | — | $0 |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $21M | -$6M | 0.0% | -39.9% | -2.0% | -1.3% | — | — | $220M |
| Mar '26 | $18M | -$5M | 0.0% | -53.6% | -1.7% | -1.0% | — | — | $288M |
| Dec '25 | $46M | $61M | 0.0% | 43.6% | 20.6% | 12.6% | -$6M | — | $168M |
| Sep '25 | $20M | $4M | 0.0% | -32.3% | 1.6% | 0.9% | -$7M | — | $175M |
| Jun '25 | $26M | $55M | 0.0% | -10.4% | 24.4% | 12.9% | — | — | $282M |
| Mar '25 | $15M | -$14M | 0.0% | -93.8% | -8.2% | -4.0% | — | — | $111M |
| Dec '24 | $19M | -$16M | 0.0% | -49.1% | -8.8% | -4.4% | -$1M | — | $38M |
| Sep '24 | $17M | -$13M | 0.0% | -64.2% | -6.8% | -3.6% | -$5M | — | $23M |
| Jun '24 | $14M | -$17M | 0.0% | -110.2% | -8.5% | -4.6% | -$4M | — | $46M |
| Mar '24 | $15M | -$12M | 0.0% | -77.3% | -5.7% | -3.1% | -$1M | — | $54M |
| Dec '23 | $18M | -$9M | 0.0% | -35.5% | -4.0% | -2.2% | -$2M | $0 | $40M |
| Sep '23 | $16M | -$9M | 0.0% | -55.8% | -3.6% | -2.2% | -$3M | — | $72M |
| Jun '23 | $14M | -$16M | 0.0% | -117.3% | -5.6% | -3.5% | -$13M | — | $106M |
| Mar '23 | $10M | -$22M | 0.0% | -239.1% | -6.0% | -4.1% | -$12M | — | $188M |
| Dec '22 | $15M | -$10M | 0.0% | -119.0% | -2.3% | -1.7% | -$124M | — | $298M |
| Sep '22 | $12M | $917M | 0.0% | -73.4% | 190.7% | 120.1% | -$22M | — | $419M |
| Jun '22 | $11M | -$8M | 0.0% | -243.2% | 2.3% | -2.3% | -$15M | $625M | $87M |
| Mar '22 | $13M | -$26M | 0.0% | -282.1% | 7.4% | -7.3% | -$26M | $621M | $94M |
| Dec '21 | $15M | -$32M | 0.0% | -375.8% | 9.5% | -8.5% | -$43M | $616M | $90M |
| Sep '21 | $13M | -$35M | 0.0% | -406.4% | 10.9% | -8.8% | -$46M | $616M | $121M |
Valuation over time
How the market has priced TBPH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 9.2× (Dec '25) to 8.4× (Sep '26).
- The price-to-sales ratio has fallen from 11.0× (Mar '23) to 8.2× (Sep '26).
P/E
P/S
Frequently asked questions
Is TBPH growing its revenue and profit?
Over the past 5 years, Theravance Biopharma, Inc.'s revenue has grown 8.4% per year. These are computed facts, not advice.
How much debt does TBPH have?
As of FY2025, Theravance Biopharma, Inc. reported — of total debt against $168M of cash; operating income covered interest expense -1.5×.
What is TBPH's profit margin?
In FY2025, gross margin was —, operating margin -3.4%, and net margin 98.5%.
What is TBPH's P/E ratio?
As of Sep '26, Theravance Biopharma, Inc. traded at a price-to-earnings ratio of about 8.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.